SOURCE: Paragon Financial Limited

Paragon Financial Limited

November 29, 2011 08:16 ET

Geron Corporation and Keryx Biopharmaceuticals Making Ground in Lucrative Cancer Drug Market

The Paragon Report Provides Equity Research on Geron Corporation & Keryx Biopharmaceuticals

NEW YORK, NY--(Marketwire - Nov 29, 2011) - According to the World Health Organization, cancer will become the leading cause of death worldwide this year. Cancer has already emerged as the most expensive disease -- costing the global economy nearly a trillion dollars a year. With cancer drugs alone costing the United States more than $30 million a year, it is clearly a lucrative sector for drug makers. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Geron Corporation (NASDAQ: GERN) and Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX). Access to the full company reports can be found at:

Research from BioMed Tracker and BIO claims that the cancer drug success rate is a mere 4.7 percent. Upon revealing the study, the agency's Oncologic Drugs Advisory Committee endorsed several FDA proposals for tightening the accelerated approval standards.

Studies from the Friends of Cancer Research advocacy group find that new cancer drugs are approved in just six months on average in the United States -- half the time it takes for the same drugs to be approved in Europe. "When we realized we were correct, we thought, 'No one is going to believe us because this goes against urban legend,'" said Ellen V. Sigal, chairwoman and founder of Friends of Cancer Research.

User fees from the Prescription Drug User Fee Act of 1992 have helped provide the FDA with resources to shorten drug review times. The Act is up for reauthorization next year, and the Friends of Cancer Research argue that the speed of drug review times might not be as high a priority as achieving other objectives in advance regulatory science.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

Earlier this month Geron Corporation announced that it is exiting the field it pioneered in a calculated business move that underscores the costly path embryonic stem cells face to become real-world products. The company acknowledged it could make more money by completing two experimental cancer drugs that are already in mid-stage testing. Geron only began testing its stem cell treatment last year after a decade of research, and it could have been a decade more before federal regulators approved it for general use.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. The company's drug candidate, KRX-0401 (perifosine), is a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at